Psychiatr. pro Praxi, 2001; 4: 185-186

Generalizovaná úzkostná porucha - její farmakoterapie

doc. MUDr. Vladimír Pidrman Ph.D, prof. MUDr. Jaroslav Bouček CSc
Psychiatrická klinika FN a LF UP, Olomouc

Published: December 31, 2001  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Pidrman V, Bouček J. Generalizovaná úzkostná porucha - její farmakoterapie. Psychiatr. praxi. 2001;2(4):185-186.

Generalizovaná úzkostná porucha (GAD - Generalized Anxiety Disorder) je chronická a rekurentní psychiatrická porucha. Její celoživotní prevalence dosahuje 5 %, poměr mezi muži a ženami je uváděn od 1:1 do 1:2. Diferenciálně diagnosticky je nutné ji odlišit především od ostatních úzkostných poruch: zvláště od panické poruchy, sociální fobie, somatizační poruchy, hypochondrické poruchy, dále od úzkosti provázející tělesná onemocnění, úzkosti při abúzu a intoxikacích psychoaktivními látkami a samozřejmě úzkosti u poruch psychotických. Vyznačuje se rovněž vysokou komorbiditou, a to jak s výše uvedenými úzkostnými poruchymi, tak s abúzem alkoholu.

Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Aldenhoff, J. (2001): Fundamental cellular principles of psychological disturbances. In: Henn, F., Sartorius, N., Helmchen, H., Lauter, H.: Contemporary psychiatry. Berlin Heidelberg New York, Springer. Vol. 1, Part 1, Chapt. 7: 120-131. Go to original source...
    2. Bazire, S. (2000): Psychotropic drug directory 2000: the professionals´ pocket handbook and aide memoire. London, Mark Allen Publishing Ltd., 324 pp.
    3. Bennet, C. J., Plum, F. (1996): Cecil textbook of medicine. 20-th. edition. Philadelphia, W. B. Saunders Comp., 2233 pp.
    4. Boyer, W. T., Feighner, J. P. (1998): The utility of SSRIs in anxious depression. In: Montgomery, S. A., den Boer, J.A.: SSRIs in depression and anxiety. Chichester, John Wiley and Sons Ltd., 101-114.
    5. Charney, D. S., Goodman, W. K., Price, L. H., Woods, S. W., Rasmussen, S. A., Heninger, G. R. (1988): Serotonin function in obsessive-compulsive disorder. Arch. Gen. Psychiatry, 45, 177-185. Go to original source... Go to PubMed...
    6. Den Boer, J. A., Slaap, B. R, Bosker, F. J. (1998): Biological aspects of anxiety disorders and depression. In: Montgomery, S. A., den Boer, J. A.: SSRIs in depression and anxiety. Chichester, John Wiley and Sons Ltd., 23-80.
    7. Braunwald, E. (1998): Harrison´s Principles of Internal Medicine. New York, McGraw-Hill Book Company, 2918 pp.
    8. Henn, F., Hitzemann, R. J.: Neurochemistry (2001): the basis of psychopharmamacology. In: Henn, F., Sartorius, N., Helmchen, H., Lauter, H.: Contemporary psychiatry. Berlin Heidelberg New York, Springer, Vol. 1, Part 1, Chapt. 6, 98-118. Go to original source...
    9. Kaplan, H. I., Sadock, B. J., Grebb, J. A. (1998): Synopsis of psychiatry. Baltimore, Williams and Wilkins, 1402 pp.
    10. Linden, M., Zubragel, D. (2001): Anxiety disorders: diagnosis and epidemiology. In: Henn, F., Sartorius, N., Helmchen, H., Lauter, H.: Contemporary psychiatry. Berlin Heidelberg New York, Springer. Vol. 3, Part 2, Chapt. 2, 16-24.
    11. Lindsay De Vane, C.: Commentary on the tolerabillity and safety of newer antidepressants. In.: Sacchetti, E., Spano, P. F. (2000): Advances in preclinical and clinical psychiatry. San Donato Milanese, Excerpta Medica, Vol. 1, pp. 105-116.
    12. Montgomery, S. (1999): SSRIs and social anaxiety. London, Science Press, Ltd, 70p.
    13. Nutt, D., Argyropolous, S., Forshall, S. (1998): Genaralized anxiety disorder. London, Martin Dunitz, Ltd., 78 pp. Pidrman, V. (2000): Nemocný s obsedantně kompulzivní poruchou. Příručka pro pacienty. Praha, Galén, 32 pp. Go to original source...
    14. Pidrman, V. (1999): Depresivní onemocnění v lékařské praxi. 2. část. Causa subita 2, 4: 11-13.
    15. Preskorn, S. H. (1996): Clinical pharmacology of selective serotonin reuptake inhibitors. Caddo, Professional Communications, Inc., 256 pp.
    16. Preskorn, S. H. (1999): Outpatient managemet of depression. Caddo, Professional Communications, Inc. 256 pp.
    17. Preskorn, S. H., Dorey, R. C., Jerkovich, G. S. (1988): Therapeutic drug monitoring of tricyclic antidepressants. Clin. Chem. 34, 5: 822-828. Go to original source...
    18. Psychotropics (2000/2001). Copenhagen, Herrman and Fischer A/S, 772 pp.
    19. Raboch, J. (2000): Můžeme vyléčit depresi? Galén, Praha, 32 pp.
    20. Remschmidt, H., Schmidt, M. H. (2001): Psychopharmacological treatment. In: Henn, F., Sartorius, N., Helmchen, H., Lauter, H.: Contemporary psychiatry. Berlin Heidelberg New York, Springer. Vol. 2, Part 1, Chapt. 6, 53-59.
    21. Robertson, M. M., Katona, C. L. E. (1997): Depression and physical illness. John Wiley and Sons Ltd. Chichester, West Sussex, 564 pp.
    22. Shiloh, R., Nutt, D., Weizman, A. (2000): Atlas of psychiatric pharmacotherapy. London, Martin Dunitz Ltd., 235 pp.
    23. Schatzberg, A. F., DeBattista, Ch., Overman, G. P., Ereshevsky, L. (1998): The 1998 black book of psychotropic dosing and monitoring. New York, MBL Communications, Inc., 40 pp.
    24. Stahl, S. M. (1998): Psychopharmacology of antidepressants. London, Martin Dunitz, Ltd, 114 pp.
    25. Stahl, S. M. (2000): Essential psychopharmacology of depression and bipolar disorder. Cambridge university press, New York, 176 pp.
    26. Švestka, J. (1998): SSRI - léky prvé volby. Praha, Maxdorf s.r.o., 160 pp.
    27. Tasman, A., Kay, J., Lieberman, J. A. (1998): Pocket companion to accompany psychiatry. Philadelphia, W.B. Sounders Comp., 631 p.
    28. Westenberg, H. G. M., den Boer, J. A. (1999): Social anxiety disorder. Amsterdam, Syn-Thesis Pudlishers, 222 pp.

    Return to the content


    Psychiatry for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.